Toronto, Canada - April 14, 2005 - The Blueprint Initiative, a research program led by Dr. Christopher Hogue at Mount Sinai Hospital’s Samuel Lunenfeld Research Institute, announced today that it has released the SMID-Genomes small-molecule binding annotation and comparison tool that it expects will dramatically accelerate lead development in antimicrobial drug discovery and allow chemists to develop safer, more specific herbicides and pesticides with fewer side effects.
